UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

Clinical pharmacology and therapeutics, 2019-01, Vol.105 (1), p.229-241

2019

Volltextzugriff (PDF)

Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children

Clinical pharmacology and therapeutics, 2018-07, Vol.104 (1), p.188-200

2018

Volltextzugriff (PDF)

Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia

European journal of clinical pharmacology, 2020-03, Vol.76 (3), p.349-361

2020

Volltextzugriff (PDF)

In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics

Drug metabolism and disposition, 2011-04, Vol.39 (4), p.703-710

2011

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies

Cancer chemotherapy and pharmacology, 2022-03, Vol.89 (3), p.373-382

2022

Volltextzugriff (PDF)

Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas

Cancer chemotherapy and pharmacology, 2021-08, Vol.88 (2), p.189-202

2021

Volltextzugriff (PDF)

Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents

Biopharmaceutics & drug disposition, 2014-09, Vol.35 (6), p.341-352

2014

Volltextzugriff (PDF)

Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors

Cancer chemotherapy and pharmacology, 2021-09, Vol.88 (3), p.451-464

2021

Volltextzugriff (PDF)

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

Frontiers in immunology, 2022-11, Vol.13, p.1026964-1026964

2022

Volltextzugriff (PDF)

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

CPT: pharmacometrics and systems pharmacology, 2019-07, Vol.8 (7), p.489-499

2019

Volltextzugriff (PDF)

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

CPT: pharmacometrics and systems pharmacology, 2020-08, Vol.9 (8), p.419-427

2020

Volltextzugriff (PDF)

Evolving drug regulatory landscape in China: A clinical pharmacology perspective

Clinical and translational science, 2021-07, Vol.14 (4), p.1222-1230

2021

Volltextzugriff (PDF)

Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine

Drug metabolism and disposition, 2010-05, Vol.38 (5), p.863-870

2010

Volltextzugriff (PDF)

Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series

Pharmaceutics, 2022-05, Vol.14 (5), p.1010

2022

Volltextzugriff (PDF)

Development of a physiologically based pharmacokinetic model to predict the effects of flavin‐containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure

Biopharmaceutics & drug disposition, 2017-09, Vol.38 (6), p.389-393

2017

Volltextzugriff (PDF)

Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover QT/QTc Study in Healthy Subjects

Clinical therapeutics, 2016-12, Vol.38 (12), p.2555-2566

2016

Volltextzugriff (PDF)

Liquid chromatography–tandem mass spectrometry method for measurement of nicotine N-glucuronide: A marker for human UGT2B10 inhibition

Journal of pharmaceutical and biomedical analysis, 2011-07, Vol.55 (5), p.964-971

2011

Volltextzugriff (PDF)

Metabolism of a G protein-coupled receptor modulator, including two major 1,2,4-oxadiazole ring-opened metabolites and a rearranged cysteine-piperazine adduct

Drug metabolism and disposition, 2012-06, Vol.40 (6), p.1151-1163

2012

Volltextzugriff (PDF)

Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions

Drug metabolism and disposition, 2006-06, Vol.34 (6), p.976-983

2006

Volltextzugriff (PDF)

Physiologically Based Absorption Modelling to Explore the Formulation and Gastric pH Changes on the Pharmacokinetics of Acalabrutinib

Pharmaceutical research, 2023-02, Vol.40 (2), p.375-386

2023

Volltextzugriff (PDF)

In vitro and in vivo metabolism of a selective δ-opioid receptor

Drug metabolism and disposition, 2011-10, Vol.39 (10), p.1883-1894

2011

Volltextzugriff (PDF)

Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology

Clinical pharmacology and therapeutics, 2024-08, Vol.116 (2), p.315-327

2024

Volltextzugriff (PDF)

PosMLP-Video: Spatial and Temporal Relative Position Encoding for Efficient Video Recognition

International journal of computer vision, 2024-06

2024

Volltextzugriff (PDF)

Preclinical pharmacology and pharmacokinetics of AZD3783, a selective 5-hydroxytryptamine 1B receptor antagonist

The Journal of pharmacology and experimental therapeutics, 2011-11, Vol.339 (2), p.567-578

2011

Volltextzugriff (PDF)

Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours

Clinical pharmacokinetics, 2024-08, Vol.63 (8), p.1191-1204

2024

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(90)
Dissertationen
(2)

Sprache

Englisch
(92)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations

Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children

Selecting the dosage of ceftazidime–avibactam in the perfect storm of nosocomial pneumonia

In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics

Pharmacokinetics and pharmacodynamics of MEDI0680, a fully human anti-PD-1 monoclonal antibody, in patients with advanced malignancies

Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas

Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents

Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Evolving drug regulatory landscape in China: A clinical pharmacology perspective

Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine

Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series

Development of a physiologically based pharmacokinetic model to predict the effects of flavin‐containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure

Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-Controlled Crossover QT/QTc Study in Healthy Subjects

Liquid chromatography–tandem mass spectrometry method for measurement of nicotine N-glucuronide: A marker for human UGT2B10 inhibition

Metabolism of a G protein-coupled receptor modulator, including two major 1,2,4-oxadiazole ring-opened metabolites and a rearranged cysteine-piperazine adduct

Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions

Physiologically Based Absorption Modelling to Explore the Formulation and Gastric pH Changes on the Pharmacokinetics of Acalabrutinib

In vitro and in vivo metabolism of a selective δ-opioid receptor

Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in Oncology

PosMLP-Video: Spatial and Temporal Relative Position Encoding for Efficient Video Recognition

Preclinical pharmacology and pharmacokinetics of AZD3783, a selective 5-hydroxytryptamine 1B receptor antagonist

Population Pharmacokinetics of Capivasertib in Patients with Advanced or Metastatic Solid Tumours

Suchergebnisse filtern